Skip to main content Back to Top
Advertisement

7/22/2021

Hypromellose Ophthalmic Solution

Products Affected - Description

    • Gonak, Akorn, 2.5%, 15 mL NDC 17478-0064-12
    • Goniosoft, OCuSOFT, 2.5%, 15 mL NDC 54799-0503-15 - discontinued
    • Goniotaire, Altaire, 2.5%, 15 mL NDC 59390-0182-13
    • Goniovisc, Hub Pharmaceuticals, 2.5%, 15 mL NDC 17238-0610-15 - discontinued

Reason for the Shortage

    • Akorn did not provide a reason for the shortage.1
    • HUB Pharmaceuticals has discontinued Goniovisc.2
    • Altaire has Goniotaire on shortage due to a voluntary recall.[3]
    • OcuSoft has discontinued Goniosoft.[4]

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Akorn has Gonak 2.5% ophthalmic solution in 15 mL bottles on back order and the company estimates a release date in late-July 2021.[1]
    • Altaire has Goniotaire 2.5% ophthalmic solution in15 mL bottles on back order and the company estimates a release date in January 2022.[3]

Alternative Agents & Management

    • Hypromellose-containing products are used in ocular examinations and to treat dry eye.[5] There are products available ranging from hypromellose 0.2% to 2.5%.[5] The American Academy of Ophthalmology does not recommend a specific product over another.[6] Use products without preservatives if applying more than 4 times daily.[6]

References

    1. Akorn (personal communication). June 8, July 13, September 7, October 25, December 13 and 26, 2018; March 1, May 8, July 29, September 17, December 18, 2019; January 30, April 27, June 30, and September 9 and 30, 2020; January 12, April 7, May 14, June 30, and July 21, 2021.
    2. HUB Pharmaceuticals (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8, July 29, September 13, October 2, December 18, 2019; January 28, April 27, and September 9, 2020; April 6, 2021.
    3. Altaire Pharmaceuticals (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8 and 22, September 17, and December 18, 2019; September 10, 2020; January 12, April 5, and July 1, 2021.
    4. Ocusoft/Cynacon (personal communication). June 8, July 11, September 5, October 25, December 13, 2018; May 8, July 29, September 17, December 18, 2019; and July 1, 2020.
    5. Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc; 2018.
    6. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Patern Guidelines. Dry Eye Syndrome. American Academy of Ophthalmology website. www.aao.org/ppp. 2013. Accessed June 11, 2018.

Updated

Updated July 22, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 8, 2018 by Anthony Trovato, PharmD, BCPS. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.